ad

Top 3 Pharma Stocks to Watch in 2027: Divi's Labs, Mankind Pharma and Aurobindo Pharma

Divi's Labs Rs 11,049.00, Q2 PAT +63.6%. Mankind Pharma Rs 2,625.00, Q2 PAT +37.7%. Aurobindo Pharma Rs 1,796.30, Q2 PAT +32.5%. Prices as of 18 Nov 2026.


19 Nov 2026 • 1:09 pm

Top 3 Pharma Stocks to Watch in 2027: Divi's Labs, Mankind Pharma and Aurobindo Pharma

Quick Answer

The pharma stocks to watch in 2027 are Divi's Laboratories, Mankind Pharma and Aurobindo Pharma, based on their latest results, returns and balance sheets. Divi's Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The best figures in the group are 63.6% quarterly profit growth, a PE of 25.99 and a return on equity of 18.69%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.

The pharma stocks to watch in 2027 are best picked on reported numbers. US generic launches, contract manufacturing for global drug makers and steady domestic demand are driving Indian pharma, and the three companies on this list grew September 2026 quarter profit by more than 32%.

This list covers Divi's Laboratories, Mankind Pharma and Aurobindo Pharma. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.

Click Here – Get Free Investment Predictions

Top 3 Pharma Stocks to Watch in 2027 at a Glance

Divi's Labs, Mankind Pharma and Aurobindo Pharma have a combined market capitalisation of about Rs 5.07 lakh crore. The table below compares these pharma stocks to watch in 2027 on the metrics that matter most for long-term investors.

Metric Divi's Labs Mankind Pharma Aurobindo Pharma
Company Divi's Laboratories Mankind Pharma Aurobindo Pharma
NSE Symbol DIVISLAB MANKIND AUROPHARMA
Share Price (Rs) 11,049.00 2,625.00 1,796.30
52-Week Closing High (Rs) 11,565.50 2,668.30 1,855.30
52-Week Closing Low (Rs) 5,821.00 1,927.40 1,121.70
Market Cap (Rs Cr) 2,93,874 1,09,040 1,03,626
PE Ratio 87.39 48.17 25.99
ROE 18.69% 12.76% 10.13%
Debt to Equity 0.00 0.31 0.22
Dividend Yield 0.27% 0.04% 0.22%

On valuation, the stocks trade at the following PE ratios: Divi's Labs at 87.39 against an industry PE of 40.12; Mankind Pharma at 48.17 against an industry PE of 40.12; Aurobindo Pharma at 25.99 against an industry PE of 40.12. Aurobindo Pharma trades below the industry multiple, while Divi's Labs and Mankind Pharma carry a premium that the market usually pays for faster growth or stronger returns.

Why Are These the Pharma Stocks to Watch in 2027?

These three made the list of pharma stocks to watch in 2027 because of earnings delivery and balance sheet quality. Indian pharma companies earn money in three main ways: selling branded medicines in India, exporting generic drugs to the US and Europe, and manufacturing ingredients or drugs for global pharma companies under contract. The three stocks on this list each lead one of these models.

In the September 2026 quarter, net profit grew 63.6% at Divi's Labs, 37.7% at Mankind Pharma and 32.5% at Aurobindo Pharma. Return on equity ranges from 10.13% to 18.69%, which shows how efficiently each company uses shareholder capital. Divi's Labs runs with little or no debt.

What Could Drive Pharma Stocks in 2027?

Pharma stocks in 2027 will be driven by new US generic approvals, pricing pressure in the US generics market, growth in chronic therapies in India, and contract manufacturing orders as global drug makers diversify their supply chains.

US FDA inspection outcomes are a key risk to track, since a warning letter can delay approvals from a plant. Divi's Laboratories and Aurobindo Pharma are constituents of the Nifty Pharma, so their results move the sector index.

1. Divi's Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet

Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesised molecules for global pharma companies, and it is one of the world's largest makers of several generic APIs.

Divi's Labs Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 3,770 2,860 +31.8%
Net Profit (Rs Cr) 1,127 689 +63.6%
Revenue FY26 vs FY25 (Rs Cr) 11,067 9,712 +14.0%
Net Profit FY26 vs FY25 (Rs Cr) 2,568 2,191 +17.2%

For FY26, revenue came in at Rs 11,067 crore (+14.0%), and net profit rose 17.2% to Rs 2,568 crore.

What to Watch in Divi's Labs for 2027

Divi's Labs grew September 2026 quarter net profit 63.6% to Rs 1,127 crore on 31.8% higher revenue, the fastest in this group, and it has the highest ROE at 18.69% with no debt. Its PE of 87.39 is far above the industry PE of 40.12, so investors should be careful about valuation and track new custom synthesis contracts. The stock closed at Rs 11,049.00 on 18 November 2026, about 4.5% below its 52-week closing high of Rs 11,565.50 and 89.8% above its 52-week closing low of Rs 5,821.00.

2. Mankind Pharma: Domestic Branded Medicines Leader

Mankind Pharma is one of India's largest domestic pharma companies by sales volume, known for brands such as Manforce, Prega News and Gas-O-Fast, with a strong presence in smaller towns.

Mankind Pharma Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 4,432.71 3,789.03 +17.0%
Net Profit (Rs Cr) 716.12 520.18 +37.7%
Revenue FY26 vs FY25 (Rs Cr) 14,636.43 12,744.23 +14.8%
Net Profit FY26 vs FY25 (Rs Cr) 1,938.10 2,006.59 Lower YoY

For FY26, revenue came in at Rs 14,636.43 crore (+14.8%), and net profit stood at Rs 1,938.10 crore. Net profit has compounded at about 7.5% a year from FY22 to FY26.

What to Watch in Mankind Pharma for 2027

Mankind Pharma grew September 2026 quarter net profit 37.7% to Rs 716.12 crore on 17.0% higher revenue. Investors should track the integration of its Bharat Serums and Vaccines acquisition, which added women's health and critical care products. The stock closed at Rs 2,625.00 on 18 November 2026, about 1.6% below its 52-week closing high of Rs 2,668.30 and 36.2% above its 52-week closing low of Rs 1,927.40.

Compare Pharma Stocks on the Univest Screener

3. Aurobindo Pharma: US Generics Leader at the Lowest PE

Aurobindo Pharma is one of the largest Indian exporters of generic medicines to the US and Europe, with a wide portfolio of oral, injectable and biosimilar products.

Aurobindo Pharma Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 10,431.51 8,406.29 +24.1%
Net Profit (Rs Cr) 1,123.84 848.13 +32.5%
Revenue FY26 vs FY25 (Rs Cr) 34,145.17 32,345.58 +5.6%
Net Profit FY26 vs FY25 (Rs Cr) 3,502.97 3,483.57 +0.6%

For FY26, revenue came in at Rs 34,145.17 crore (+5.6%), and net profit rose 0.6% to Rs 3,502.97 crore. Net profit has compounded at about 7.3% a year from FY22 to FY26.

What to Watch in Aurobindo Pharma for 2027

Aurobindo Pharma grew September 2026 quarter net profit 32.5% to Rs 1,123.84 crore and revenue 24.1% to Rs 10,431.51 crore. It trades at a PE of 25.99, the lowest of the three and below the industry PE of 40.12. Investors should track US FDA inspection outcomes and its biosimilars pipeline. The stock closed at Rs 1,796.30 on 18 November 2026, about 3.2% below its 52-week closing high of Rs 1,855.30 and 60.1% above its 52-week closing low of Rs 1,121.70.

How Do Divi's Labs, Mankind Pharma and Aurobindo Pharma Compare?

The table below puts quarterly growth, annual profit, valuation and price position for the three pharma stocks side by side.

Metric Divi's Labs Mankind Pharma Aurobindo Pharma
Q2 Net Profit Growth +63.6% +37.7% +32.5%
Latest Annual Net Profit (Rs Cr) 2,568 1,938.10 3,502.97
PE vs Industry PE 87.39 vs 40.12 48.17 vs 40.12 25.99 vs 40.12
Distance from 52-Week Closing High 4.5% below 1.6% below 3.2% below

For investors building a list of pharma stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum and capital efficiency may track Divi's Labs and investors who want valuation comfort may prefer Aurobindo Pharma. Mankind Pharma gives exposure to a different part of the sector.

Key Risks for Pharma Stocks in 2027

Even the strongest pharma stocks to watch in 2027 carry risks that investors should weigh before buying.

US pricing pressure: Price erosion in US generics can reduce margins even when volumes grow.

Regulatory action: US FDA warning letters or import alerts can stop shipments from a plant.

Currency moves: A stronger rupee reduces the value of export revenue.

Valuation: Divi's Labs and Mankind Pharma trade above the industry PE, so a slowdown in growth can lead to price corrections. Staggered buying helps manage entry risk.

Download the Univest iOS App or Univest Android App to track Divi's Labs, Mankind Pharma and Aurobindo Pharma live and get daily stock research.

Conclusion

Divi's Laboratories, Mankind Pharma and Aurobindo Pharma stand out among pharma stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock's PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with US pricing pressure.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Pharma Stocks to Watch in 2027

Which are the best pharma stocks to watch in 2027?

Ans. Divi's Laboratories, Mankind Pharma and Aurobindo Pharma are three of the strongest pharma stocks to watch in 2027 based on reported numbers. Divi's Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The strongest figures in the group are 63.6% quarterly profit growth, a 18.69% return on equity and a PE of 25.99. Each company covers a different part of the pharma space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.

Which pharma stock has grown profit the fastest?

Ans. Divi's Laboratories has grown profit the fastest among these three, with September 2026 quarter net profit up 63.6% year on year to Rs 1,127 crore. Mankind Pharma follows with 37.7% growth. Divi's Labs's latest annual net profit stood at Rs 2,568 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.

Which of these pharma stocks is the most attractively valued?

Ans. Aurobindo Pharma is the most attractively valued of the three, with a PE of 25.99 against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Labs at 87.39. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.

Which pharma stock has the lowest valuation?

Ans. Aurobindo Pharma has the lowest valuation of the three with a PE of 25.99, against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Laboratories at 87.39. Aurobindo's lower PE reflects its exposure to the price-competitive US generics market, while Divi's commands a premium for its contract manufacturing model and debt-free balance sheet. Investors should compare profit growth and return on equity along with the PE before deciding, since Divi's also grew quarterly profit the fastest at 63.6%.

What are the key risks for pharma stocks in 2027?

Ans. The main risks for pharma stocks in 2027 are US pricing pressure, regulatory action and currency moves. Price erosion in US generics can reduce margins even when volumes grow. Valuation is another risk, since Divi's Labs and Mankind Pharma trade above the industry PE. US FDA warning letters or import alerts can stop shipments from a plant. A stronger rupee reduces the value of export revenue. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.

Should I invest in pharma stocks for the long term?

Ans. Pharma stocks can suit long-term investors who understand the sector's cycles and are comfortable with price swings. Divi's Labs, Mankind Pharma and Aurobindo Pharma have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Divi's Labs earns a 18.69% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down